Clinical Trials

    Showing 1 - 10 of 10 skin cancer

    A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

    Status: Open Not Enrolling

    Investigator: Ryan Kieser

    Study Coordinator:

    Phone:

    To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.... Read more >

    Acupuncture Trial

    Status: Open Not Enrolling

    Investigator: Polly Niravath

    Study Coordinator: Milan Sheth

    Phone: 713.790.3311

    A single arm pilot study of 20 patients will be used to determine the feasibility of EA as a treatment for cancer survivors who have been treated with curative intent, but who have persistent CIPN for ?3 months after the cancer treatment is completed... Read more >

    IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)

    Status: Open Not Enrolling

    Investigator: Ryan Kieser

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of... Read more >

    Neoadjuvant Atezolizumab in Patients With Non-Metastatic Resectable High-Risk Cutaneous Melanoma

    Status: Open Not Enrolling

    Investigator: Nestor Esnaola

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metastatic) ... Read more >

    NWBT 020221 - DC-Vax

    Status: Open Not Enrolling

    Investigator: David Baskin

    Study Coordinator: Helga Jones

    Phone: 713.363.9388

    " Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site prior ... Read more >

    Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

    Status: Enrolling

    Investigator: Monisha Singh

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1) vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care (SoC),... Read more >

    Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair

    Status: Open Not Enrolling

    Investigator: Jun Zhang

    Study Coordinator: Derek Cole

    Phone: 713.441.5607

    The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), class... Read more >

    Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy

    Status: Enrolling

    Investigator: David Baskin

    Study Coordinator: Melissa Daly

    Phone: 713.441.3834

    NCT03603405 This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma multifor... Read more >

    Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy Combination with Radiotherapy and Chemotherapy for Recurrent Glioblastoma Multiforme

    Status: Enrolling

    Investigator: David Baskin

    Study Coordinator: Melissa Daly

    Phone: 713.441.3834

    NCT03596086 This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma multi... Read more >

    Testing the Addition of Trastuzumab or Trastuzumab/?Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer

    Status: Enrolling

    Investigator: Aparna Kamat

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in ... Read more >